



Clinical trial results:

A Phase I/II single-arm trial to evaluate the combination of cisplatin and gemcitabine with the mTOR inhibitor temsirolimus for treatment of advanced cancers, including first-line treatment of patients with advanced transitional cell carcinoma of the urothelium.

Summary

EudraCT number	2007-007615-82
Trial protocol	GB
Global end of trial date	15 March 2017

Results information

Result version number	v1 (current)
This version publication date	13 May 2017
First version publication date	13 May 2017
Summary attachment (see zip file)	CONSORT diagram (CONSORT diagram.jpg) TOTEM upload (TOTEM, ct_result_2007-007615-82.pdf)

Trial information

Trial identification

Sponsor protocol code	SPON417-07
-----------------------	------------

Additional study identifiers

ISRCTN number	ISRCTN31546330
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Cardiff University
Sponsor organisation address	30-36 Newport Road, Cardiff, United Kingdom,
Public contact	Ms Angela Casbard, Centre for Trials Research, 02920 687470, casbardac@cardiff.ac.uk
Scientific contact	Ms Angela Casbard, Centre for Trials Research, 02920 687470, casbardac@cardiff.ac.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 March 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	15 March 2017
Global end of trial reached?	Yes
Global end of trial date	15 March 2017
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The overall objective of this trial is to assess whether the addition of temsirolimus to standard cisplatin/gemcitabine cancer chemotherapy is a safe and effective treatment for patients with advanced malignancy and an effective treatment for patients with advanced urothelial cancer.

Phase I of the trial aims to establish the appropriate dose and schedule of temsirolimus when used in combination with gemcitabine and and cisplatin for patients with advanced non-haematological malignancy.

Phase II of the trial aims to establish activity, safety and feasibility of this combination in participants with advanced transitional cell carcinoma of the urothelium. Activity will be measured by determining the number of patients who are alive at six months and have responded completely or partially to treatment or who have stable disease, according to strict radiological criteria i.e. progression-free survival (PFS) six months after enrolment.

Protection of trial subjects:

The safety review committee (SRC) met to review each cohort of 3 patients and to decide whether or not to escalate to the next dose level, to recruit additional participants at the current dose level or to discontinue dose escalation.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	31 December 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 15
Worldwide total number of subjects	15
EEA total number of subjects	15

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	8
From 65 to 84 years	7
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Trial open date: 31 December 2012 and Open for 38 months. Recruitment was stopped August 2015.

Pre-assignment

Screening details:

Main Inclusion Criteria: For all participants: 1) Locally advanced and/or metastatic disease. Not suitable for radical radiotherapy or curative surgery 2) Life expectancy ≥ 3 months 3) WHO Performance status 0-2 4) Fit to receive cisplatin-containing combination chemotherapy 5) Informed consent.

Period 1

Period 1 title	Full trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Experimental
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Temsirolimus
Investigational medicinal product code	
Other name	Torisel
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous bolus use
Dosage and administration details:	
10 mg at different days per cohort	
Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for injection/infusion
Routes of administration	Intravenous bolus use
Dosage and administration details:	
70 mg day 1 of every cycle	
Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for injection/infusion
Routes of administration	Intravenous bolus use
Dosage and administration details:	
1000 mg day 1, 8	

Number of subjects in period 1^[1]	Experimental
Started	14
Completed	7
Not completed	7
Consent withdrawn by subject	1
Physician decision	2
Disease progression	1
Adverse event, non-fatal	2
Poor rationale for treatment in palliative setting	1

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: One patient was found to not be eligible so did not receive any trial treatment or provide any data to the trial

Baseline characteristics

Reporting groups

Reporting group title	Experimental
-----------------------	--------------

Reporting group description: -

Reporting group values	Experimental	Total	
Number of subjects	14	14	
Age categorical			
Units: Subjects			
Age continuous			
Units: years			
median	63.5		
full range (min-max)	40 to 80	-	
Gender categorical			
Units: Subjects			
Female	9	9	
Male	5	5	
Non-Urothelial Cancer Histology			
Units: Subjects			
Adenocarcinoma	2	2	
Adenosquamous Carcinoma	1	1	
Poorly differentiated/ insular carcinoma	1	1	
Large cell undifferentiated carcinoma	1	1	
Cholangiocarcinoma of biliary tract	1	1	
Non-small cell carcinoma	1	1	
Ovarian clear cell carcinoma	1	1	
Not applicable	6	6	
Location of primary disease for Non-Urothelial Cancer patients			
Units: Subjects			
Lung	3	3	
Gallbladder	1	1	
Uterus	1	1	
Thyroid	1	1	
Biliary Tract	1	1	
Ovarian	1	1	
Not applicable	6	6	
T - Stage for Non-Urothelial Cancer patients			
Units: Subjects			
TX	5	5	
T0	1	1	
T1	1	1	
T4A	1	1	
Not applicable	6	6	
N - Stage for Non-Urothelial Cancer			

patients			
Units: Subjects			
N0	5	5	
N1	3	3	
Not applicable	6	6	
M-Stage for Non-Urothelial Cancer patients			
Units: Subjects			
M1	8	8	
Not applicable	6	6	
Urothelial Cancer histology			
Units: Subjects			
Pure TCC	4	4	
Mixed TCC	1	1	
Missing	1	1	
Not applicable	8	8	
Location of primary disease for Urothelial Cancer patients			
Units: Subjects			
Bladder	3	3	
Renal Pelvis/Ureter	2	2	
Missing	1	1	
Not applicable	8	8	
T - Stage for Urothelial Cancer patients			
Units: Subjects			
TX	3	3	
T2	1	1	
T3	2	2	
Not applicable	8	8	
N - Stage for Urothelial Cancer patients			
Units: Subjects			
NX	1	1	
N0	1	1	
N1	3	3	
N3	1	1	
Not applicable	8	8	
M-Stage for Urothelial Cancer patients			
Units: Subjects			
M0	1	1	
M1	5	5	
Not applicable	8	8	
Current metastases			
Units: Subjects			
Liver	3	3	
Lung	6	6	
Bone	2	2	
Multiple	1	1	
Other	2	2	
Current nodes			
Units: Subjects			
Pelvic	3	3	
Supraclavicular	1	1	

Abdominal	2	2	
Axillary	2	2	
Multiple	3	3	
Other	3	3	
Previous (neo)adjuvant chemotherapy Units: Subjects			
Yes	9	9	
No	5	5	
Did any previous (neo)adjuvant chemotherapy include cisplatin Units: Subjects			
Yes	4	4	
No	5	5	
Missing	5	5	
Previous Radiotherapy Units: Subjects			
Yes	2	2	
No	12	12	
Median number of cycles of previous (neo)adjuvant chemotherapy Units: Number of cycles			
median	6		
full range (min-max)	3 to 18	-	

Subject analysis sets

Subject analysis set title	Treated patients
Subject analysis set type	Intention-to-treat
Subject analysis set description: One patient was deemed ineligible after they were recruited.	
Subject analysis set title	Cohort 1
Subject analysis set type	Intention-to-treat
Subject analysis set description: Cohort 1	
Subject analysis set title	Cohort 2
Subject analysis set type	Intention-to-treat
Subject analysis set description: Cohort 2	
Subject analysis set title	Cohort 3
Subject analysis set type	Intention-to-treat
Subject analysis set description: Cohort 3	
Subject analysis set title	Cohort 3b
Subject analysis set type	Intention-to-treat
Subject analysis set description: Cohort 3b	
Subject analysis set title	Urothelial Cancer Patients
Subject analysis set type	Sub-group analysis
Subject analysis set description: Urothelial Cancer Patients only	
Subject analysis set title	Non-Urothelial Cancer Patients
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Non-Urothelial Cancer Patients only

Subject analysis set title	Pure TCC patients
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Pure TCC patients only

Reporting group values	Treated patients	Cohort 1	Cohort 2
Number of subjects	14	3	3
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
median	63.5	60	72
full range (min-max)	40 to 80	50 to 68	69 to 72
Gender categorical			
Units: Subjects			
Female	9	1	2
Male	5	2	1
Non-Urothelial Cancer Histology			
Units: Subjects			
Adenocarcinoma	2	0	2
Adenosquamous Carcinoma	1	0	0
Poorly differentiated/ insular carcinoma	1	0	0
Large cell undifferentiated carcinoma	1	0	0
Cholangiocarcinoma of biliary tract	1	0	0
Non-small cell carcinoma	1	0	0
Ovarian clear cell carcinoma	1	0	0
Not applicable	6	0	0
Location of primary disease for Non-Urothelial Cancer patients			
Units: Subjects			
Lung	3	0	1
Gallbladder	1	0	1
Uterus	1	0	0
Thyroid	1	0	0
Biliary Tract	1	0	0
Ovarian	1	0	0
Not applicable	6	0	0
T - Stage for Non-Urothelial Cancer patients			
Units: Subjects			
TX	5	0	1
T0	1	0	0
T1	1	0	1
T4A	1	0	0
Not applicable	6	0	0
N - Stage for Non-Urothelial Cancer patients			
Units: Subjects			

N0	5	0	1
N1	3	0	1
Not applicable	6	0	0
M-Stage for Non-Urothelial Cancer patients Units: Subjects			
M1	8	0	2
Not applicable	6	0	0
Urothelial Cancer histology Units: Subjects			
Pure TCC	4	2	1
Mixed TCC	1	1	0
Missing	1	0	0
Not applicable	8	0	0
Location of primary disease for Urothelial Cancer patients Units: Subjects			
Bladder	3	1	1
Renal Pelvis/Ureter	2	2	0
Missing	1	0	0
Not applicable	8	0	0
T - Stage for Urothelial Cancer patients Units: Subjects			
TX	3	0	1
T2	1	1	0
T3	2	2	0
Not applicable	8	0	0
N - Stage for Urothelial Cancer patients Units: Subjects			
NX	1	0	0
N0	1	1	0
N1	3	2	1
N3	1	0	0
Not applicable	8	0	0
M-Stage for Urothelial Cancer patients Units: Subjects			
M0	1	0	0
M1	5	3	1
Not applicable	8	0	0
Current metastases Units: Subjects			
Liver	3	1	0
Lung	6	1	1
Bone	2	0	1
Multiple	1	0	0
Other	4	1	1
Current nodes Units: Subjects			
Pelvic	3	1	1
Supraclavicular	1	0	0
Abdominal	2	2	0
Axillary	2	0	0

Multiple	3	1	0
Other	5	0	1
Previous (neo)adjuvant chemotherapy Units: Subjects			
Yes	9	1	0
No	5	2	3
Did any previous (neo)adjuvant chemotherapy include cisplatin Units: Subjects			
Yes	4	0	0
No	5	1	0
Missing	5	0	0
Previous Radiotherapy Units: Subjects			
Yes	2	0	1
No	12	3	2
Median number of cycles of previous (neo)adjuvant chemotherapy Units: Number of cycles			
median	6	4	0
full range (min-max)	3 to 18	4 to 4	0 to 0

Reporting group values	Cohort 3	Cohort 3b	Urothelial Cancer Patients
Number of subjects	4	4	6
Age categorical Units: Subjects			

Age continuous Units: years			
median	70.5	56.5	64
full range (min-max)	40 to 80	47 to 57	50 to 73
Gender categorical Units: Subjects			
Female	3	3	2
Male	1	1	4
Non-Urothelial Cancer Histology Units: Subjects			
Adenocarcinoma	0	0	
Adenosquamous Carcinoma	1	0	
Poorly differentiated/ insular carcinoma	1	0	
Large cell undifferentiated carcinoma	1	0	
Cholangiocarcinoma of biliary tract	0	1	
Non-small cell carcinoma	0	1	
Ovarian clear cell carcinoma	0	1	
Not applicable	0	0	
Location of primary disease for Non- Urothelial Cancer patients Units: Subjects			
Lung	1	1	
Gallbladder	0	0	

Uterus	1	0	
Thyroid	1	0	
Biliary Tract	0	1	
Ovarian	0	1	
Not applicable	0	0	
T - Stage for Non-Urothelial Cancer patients Units: Subjects			
TX	3	1	
T0	0	1	
T1	0	0	
T4A	0	1	
Not applicable	0	0	
N - Stage for Non-Urothelial Cancer patients Units: Subjects			
N0	3	1	
N1	0	2	
Not applicable	0	0	
M-Stage for Non-Urothelial Cancer patients Units: Subjects			
M1	3	3	
Not applicable	0	0	
Urothelial Cancer histology Units: Subjects			
Pure TCC	0	1	
Mixed TCC	0	0	
Missing	1	0	
Not applicable	0	0	
Location of primary disease for Urothelial Cancer patients Units: Subjects			
Bladder	0	1	
Renal Pelvis/Ureter	0	0	
Missing	1	0	
Not applicable	0	0	
T - Stage for Urothelial Cancer patients Units: Subjects			
TX	1	1	
T2	0	0	
T3	0	0	
Not applicable	0	0	
N - Stage for Urothelial Cancer patients Units: Subjects			
NX	1	0	
N0	0	0	
N1	0	0	
N3	0	1	
Not applicable	0	0	
M-Stage for Urothelial Cancer patients Units: Subjects			

M0	0	1	
M1	1	0	
Not applicable	0	0	
Current metastases Units: Subjects			
Liver	1	1	
Lung	2	2	
Bone	1	0	
Multiple	1	0	
Other	2	0	
Current nodes Units: Subjects			
Pelvic	0	1	
Supraclavicular	0	1	
Abdominal	0	0	
Axillary	0	2	
Multiple	0	2	
Other	2	2	
Previous (neo)adjuvant chemotherapy Units: Subjects			
Yes	4	4	
No	0	0	
Did any previous (neo)adjuvant chemotherapy include cisplatin Units: Subjects			
Yes	2	2	
No	2	2	
Missing	0	0	
Previous Radiotherapy Units: Subjects			
Yes	1	0	
No	3	4	
Median number of cycles of previous (neo)adjuvant chemotherapy Units: Number of cycles			
median	10	4	
full range (min-max)	6 to 18	3 to 6	

Reporting group values	Non-Urothelial Cancer Patients	Pure TCC patients	
Number of subjects	8	4	
Age categorical Units: Subjects			

Age continuous Units: years			
median	62	64	
full range (min-max)	40 to 80	56 to 72	
Gender categorical Units: Subjects			
Female	7	0	
Male	1	4	

Non-Urothelial Cancer Histology Units: Subjects			
Adenocarcinoma Adenosquamous Carcinoma Poorly differentiated/ insular carcinoma Large cell undifferentiated carcinoma Cholangiocarcinoma of biliary tract Non-small cell carcinoma Ovarian clear cell carcinoma Not applicable			
Location of primary disease for Non-Urothelial Cancer patients Units: Subjects			
Lung Gallbladder Uterus Thyroid Biliary Tract Ovarian Not applicable			
T - Stage for Non-Urothelial Cancer patients Units: Subjects			
TX T0 T1 T4A Not applicable			
N - Stage for Non-Urothelial Cancer patients Units: Subjects			
N0 N1 Not applicable			
M-Stage for Non-Urothelial Cancer patients Units: Subjects			
M1 Not applicable			
Urothelial Cancer histology Units: Subjects			
Pure TCC Mixed TCC Missing Not applicable			
Location of primary disease for Urothelial Cancer patients Units: Subjects			
Bladder Renal Pelvis/Ureter Missing Not applicable			

T - Stage for Urothelial Cancer patients Units: Subjects			
TX T2 T3 Not applicable			
N - Stage for Urothelial Cancer patients Units: Subjects			
NX N0 N1 N3 Not applicable			
M-Stage for Urothelial Cancer patients Units: Subjects			
M0 M1 Not applicable			
Current metastases Units: Subjects			
Liver Lung Bone Multiple Other			
Current nodes Units: Subjects			
Pelvic Supraclavicular Abdominal Axillary Multiple Other			
Previous (neo)adjuvant chemotherapy Units: Subjects			
Yes No			
Did any previous (neo)adjuvant chemotherapy include cisplatin Units: Subjects			
Yes No Missing			
Previous Radiotherapy Units: Subjects			
Yes No			
Median number of cycles of previous (neo)adjuvant chemotherapy Units: Number of cycles median full range (min-max)			

End points

End points reporting groups

Reporting group title	Experimental
Reporting group description: -	
Subject analysis set title	Treated patients
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
One patient was deemed ineligible after they were recruited.	
Subject analysis set title	Cohort 1
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
Cohort 1	
Subject analysis set title	Cohort 2
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
Cohort 2	
Subject analysis set title	Cohort 3
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
Cohort 3	
Subject analysis set title	Cohort 3b
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
Cohort 3b	
Subject analysis set title	Urothelial Cancer Patients
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Urothelial Cancer Patients only	
Subject analysis set title	Non-Urothelial Cancer Patients
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Non-Urothelial Cancer Patients only	
Subject analysis set title	Pure TCC patients
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Pure TCC patients only	

Primary: Dose Limiting Toxicities

End point title	Dose Limiting Toxicities ^[1]
End point description:	
End point type	Primary
End point timeframe:	
until cycle 2, day 1	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint was purely descriptive and was reported as univariates with no statistical testing attached.

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Subjects	4			

Statistical analyses

No statistical analyses for this end point

Secondary: Deaths

End point title	Deaths
-----------------	--------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Entire trial

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Subjects				
Number	7			

Statistical analyses

No statistical analyses for this end point

Secondary: Median doses cisplatin

End point title	Median doses cisplatin
-----------------	------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Entire trial

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: doses				
median (full range (min-max))	70 (0 to 70)			

Statistical analyses

No statistical analyses for this end point

Secondary: Median doses gemcitabine

End point title	Median doses gemcitabine
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Doses				
median (full range (min-max))	750 (0 to 1000)			

Statistical analyses

No statistical analyses for this end point

Secondary: Median doses temsirolimus

End point title	Median doses temsirolimus
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Doses				
median (full range (min-max))	7.5 (0 to 10)			

Statistical analyses

No statistical analyses for this end point

Secondary: Any dose reduction

End point title	Any dose reduction
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Subjects				
Number	13			

Statistical analyses

No statistical analyses for this end point

Secondary: Median dose reduction cisplatin

End point title	Median dose reduction cisplatin
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Doses				
median (full range (min-max))	52 (0 to 68)			

Statistical analyses

No statistical analyses for this end point

Secondary: Median dose reductions gemcitabine

End point title	Median dose reductions gemcitabine
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Doses				
median (full range (min-max))	563 (0 to 750)			

Statistical analyses

No statistical analyses for this end point

Secondary: Median dose reductions temsirolimus

End point title	Median dose reductions temsirolimus
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Doses				
median (full range (min-max))	0 (0 to 0)			

Statistical analyses

No statistical analyses for this end point

Secondary: Any dose delays

End point title	Any dose delays
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Subjects				
Number	14			

Statistical analyses

No statistical analyses for this end point

Secondary: Median dose delays

End point title	Median dose delays
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Days				
median (full range (min-max))	0.5 (0 to 14)			

Statistical analyses

No statistical analyses for this end point

Secondary: Mean percent dose intensity Cisplatin

End point title	Mean percent dose intensity Cisplatin
End point description:	
End point type	Secondary
End point timeframe:	
Cycles 1-3	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Percent				
arithmetic mean (full range (min-max))	87 (87 to 87)			

Statistical analyses

No statistical analyses for this end point

Secondary: Mean percent dose intensity Gemcitabine

End point title	Mean percent dose intensity Gemcitabine
End point description:	
End point type	Secondary
End point timeframe:	
Cycles 1-3	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Percent				
arithmetic mean (full range (min-max))	73 (73 to 73)			

Statistical analyses

No statistical analyses for this end point

Secondary: Mean percent dose intensity temsirolimus

End point title	Mean percent dose intensity temsirolimus
End point description:	
End point type	Secondary
End point timeframe:	
Cycles 1-3	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Percent				
arithmetic mean (full range (min-max))	73 (73 to 73)			

Statistical analyses

No statistical analyses for this end point

Secondary: Mean percent dose intensity Cisplatin all

End point title	Mean percent dose intensity Cisplatin all
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: percent				
arithmetic mean (full range (min-max))	72 (72 to 72)			

Statistical analyses

No statistical analyses for this end point

Secondary: Mean percent dose intensity gemcitabine all

End point title	Mean percent dose intensity gemcitabine all
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: percent				
arithmetic mean (full range (min-max))	61 (61 to 61)			

Statistical analyses

No statistical analyses for this end point

Secondary: Mean percent dose intensity temsirolimus all

End point title	Mean percent dose intensity temsirolimus all
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: percent				
arithmetic mean (full range (min-max))	58 (58 to 58)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percent received at least 3 cycles of protocol treatment

End point title	Percent received at least 3 cycles of protocol treatment
End point description:	
End point type	Secondary
End point timeframe:	
First three cycles of treatment	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: percent				
number (not applicable)	26.7			

Statistical analyses

No statistical analyses for this end point

Secondary: Withdrawal, drop outs or discontinuations

End point title	Withdrawal, drop outs or discontinuations
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Subjects				
Number	8			

Statistical analyses

No statistical analyses for this end point

Secondary: AE greater than Grade 3

End point title	AE greater than Grade 3
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Number of AEs	58			

Statistical analyses

No statistical analyses for this end point

Secondary: Any AE

End point title	Any AE
End point description:	
End point type	Secondary
End point timeframe:	
Entire trial	

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Number of toxicities	729			

Statistical analyses

No statistical analyses for this end point

Secondary: Serious AEs

End point title	Serious AEs
-----------------	-------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Entire trial

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Number of toxicities	10			

Statistical analyses

No statistical analyses for this end point

Secondary: Serious Adverse Reactions

End point title	Serious Adverse Reactions
-----------------	---------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Entire trial

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Number of toxicities	2			

Statistical analyses

No statistical analyses for this end point

Secondary: AE leading to discontinuation of temsirolimus

End point title	AE leading to discontinuation of temsirolimus
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Entire trial

End point values	Experimental			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Number of toxicities	3			

Statistical analyses

No statistical analyses for this end point

Secondary: Disease response at the end of cycle 3

End point title	Disease response at the end of cycle 3
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

End of cycle 3

End point values	Treated patients	Urothelial Cancer Patients	Non-Urothelial Cancer Patients	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	14	6	8	
Units: Subjects				
CR	0	0	0	
PR	5	4	1	
SD	8	2	6	
PD	0	0	0	
NE	0	0	0	
Withdrawn but consented to follow up and missed vi	1	0	1	
Missing	0	0	0	
Died	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Disease response at the end of cycle 6

End point title	Disease response at the end of cycle 6
End point description:	
End point type	Secondary
End point timeframe:	
End of cycle 6	

End point values	Treated patients	Urothelial Cancer Patients	Non-Urothelial Cancer Patients	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	14	6	8	
Units: Subjects				
CR	0	0	0	
PR	5	4	1	
SD	1	0	1	
PD	2	1	1	
NE	0	0	0	
Withdrawn but consented to follow up and missed vi	5	1	4	
Missing	0	0	0	
Died	1	0	1	

Statistical analyses

No statistical analyses for this end point

Secondary: Disease response at 6 months

End point title Disease response at 6 months

End point description:

End point type Secondary

End point timeframe:

6 months follow up

End point values	Treated patients	Urothelial Cancer Patients	Non-Urothelial Cancer Patients	Pure TCC patients
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	14	6	8	4
Units: Subjects				
CR	1	1	0	1
PR	0	0	0	0
SD	1	0	1	0
PD	7	4	3	2
NE	0	0	0	0
Withdrawn but consented to follow up and missed vi	4	1	3	1
Missing	0	0	0	0
Died	1	0	1	0

Statistical analyses

No statistical analyses for this end point

Secondary: Disease response at 12 months

End point title Disease response at 12 months

End point description:

End point type Secondary

End point timeframe:

12 months follow up

End point values	Treated patients	Urothelial Cancer Patients	Non-Urothelial Cancer Patients	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	14	6	8	
Units: Subjects				
CR	1	1	0	
PR	0	0	0	

SD	0	0	0	
PD	1	1	0	
NE	0	0	0	
Withdrawn but consented to follow up and missed vi	4	1	3	
Missing	3	1	2	
Died	5	2	3	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Cycles 1-6, 6 and 12 months follow up

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	CTCAE
-----------------	-------

Dictionary version	4.03
--------------------	------

Reporting groups

Reporting group title	Experimental
-----------------------	--------------

Reporting group description: -

Serious adverse events	Experimental		
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 14 (57.14%)		
number of deaths (all causes)	7		
number of deaths resulting from adverse events	0		
Investigations			
Neutropenia fever			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenic Sepsis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			

Vasovagal reaction			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Ano-rectal infection			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lung infection			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Metabolism and nutrition disorders			
Hypomagnesaemia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Low Potassium			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Experimental		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	14 / 14 (100.00%)		
Vascular disorders			
Thromboembolic event			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	3		
Phlebitis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Hypertension			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	3		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	12 / 14 (85.71%)		
occurrences (all)	47		
Fever			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	3		
Lethargy			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	14		
Flu like symptoms			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Weight loss			
subjects affected / exposed	4 / 14 (28.57%)		
occurrences (all)	6		
Oral thrush			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Gastro-oesophageal reflux disease			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Inflammation in right wrist (possibly related to last infusion)			

subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Periorbital oedema			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	4		
Occasional headaches			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	4		
Dehydration			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Sore throat			
subjects affected / exposed	4 / 14 (28.57%)		
occurrences (all)	7		
Flecks of blood when blowing nose			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Runny nose			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Dry mouth			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	3		
Mouth ulcers			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Mouth soreness			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Right eye bloodshot			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Urine stream stop/start			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Skin rash - left upper chest (insect			

bite)			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Left arm cellulitis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Bleeding (bruise) left arm - picc line insertion			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Swollen right hand			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	5		
Swollen left hand			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	5		
Allergic reaction			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Watering eyes			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Myalgias			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Left forearm swelling and pain			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Pins and needles in hands and feet			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Hot flushes			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Night sweats			

subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	7 / 14 (50.00%)		
occurrences (all)	19		
Epistaxis			
subjects affected / exposed	6 / 14 (42.86%)		
occurrences (all)	8		
Nose bleeds			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Cough			
subjects affected / exposed	7 / 14 (50.00%)		
occurrences (all)	17		
Haemoptysis/bronchopulmonary haemorrhage			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Insomnia			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Investigations			
ALT increased			
subjects affected / exposed	5 / 14 (35.71%)		
occurrences (all)	12		
AST increased			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	3		
Cholesterol high			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	3		
Creatinine increased			

subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
GGT increased			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	5		
Lymphocyte count decreased			
subjects affected / exposed	5 / 14 (35.71%)		
occurrences (all)	15		
Neutrophil count decreased			
subjects affected / exposed	12 / 14 (85.71%)		
occurrences (all)	36		
Platelet count decreased			
subjects affected / exposed	11 / 14 (78.57%)		
occurrences (all)	30		
White blood cell count increased			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	3		
Increased platelets			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	10		
Thrombocytopaenia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Peripheral sensory neuropathy			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	9		
Dysgeusia (taste)			

subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	9		
Altered taste			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	4		
Neuropathy in left hand of uncertain origin			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	5		
Hypersensitivity to smells			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	5		
Headache			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Paresthesia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	8 / 14 (57.14%)		
occurrences (all)	33		
Superficial left vein thrombosis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Ear and labyrinth disorders			
Hearing impaired			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	3		
Tinnitus			
subjects affected / exposed	5 / 14 (35.71%)		
occurrences (all)	16		
External otitis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Eye disorders			

Inflamed left eye lid subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 2		
Gastrointestinal disorders			
Abdominal Pain subjects affected / exposed occurrences (all)	7 / 14 (50.00%) 14		
Constipation subjects affected / exposed occurrences (all)	10 / 14 (71.43%) 27		
Diarrhoea subjects affected / exposed occurrences (all)	7 / 14 (50.00%) 14		
Nausea subjects affected / exposed occurrences (all)	14 / 14 (100.00%) 46		
Vomiting subjects affected / exposed occurrences (all)	9 / 14 (64.29%) 20		
Stomatitis subjects affected / exposed occurrences (all)	2 / 14 (14.29%) 4		
Mucositis subjects affected / exposed occurrences (all)	8 / 14 (57.14%) 16		
Abdominal cramping subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Haemorrhoids subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Gastric reflux subjects affected / exposed occurrences (all)	2 / 14 (14.29%) 2		
Blisters on tongue			

subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Sub acute bowel obstruction			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	5		
Eczema (non infected)			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	6		
Alopecia			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	6		
Rash maculo-papular			
subjects affected / exposed	5 / 14 (35.71%)		
occurrences (all)	11		
Folliculitis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Itchy skin			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Skin rash			
subjects affected / exposed	6 / 14 (42.86%)		
occurrences (all)	12		
Dry skin			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	9		
Acne form rash anterior chest			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Renal and urinary disorders			
Haematuria			

subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Urinary frequency			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	5		
Nocturia			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	7		
Dysuria			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	3		
Left loin pain			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Urinary urgency			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Proteinuria			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Endocrine disorders			
Salivary gland secretion increase			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	3		
Hypothyroidism			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Leg pain			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Coccygeal pain			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Cramp (calf muscle)			

subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Left chest wall pain			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	5		
Bilateral ankle oedema			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	5		
Chest wall discomfort			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Back pain			
subjects affected / exposed	6 / 14 (42.86%)		
occurrences (all)	8		
Back pain and left leg pain			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	5		
Whole body pain			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Pelvic pain			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Cramp (hands and toes)			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Infections and infestations			
Upper respiratory infection			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	4		
Lower respiratory tract infection (chest)			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Chest infection			

subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Cellulitis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Metabolism and nutrition disorders			
Hypomagnesemia			
subjects affected / exposed	6 / 14 (42.86%)		
occurrences (all)	16		
Hyponatraemia			
subjects affected / exposed	4 / 14 (28.57%)		
occurrences (all)	15		
Hypophosphataemia			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	7		
Hyperglycaemia			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	4		
Hypokalaemia			
subjects affected / exposed	7 / 14 (50.00%)		
occurrences (all)	9		
Appetite lost			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	3		
Reduced appetite			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	3		
Anorexia			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	4		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 August 2011	<p>Change of documents: Cover Letter 18/08/2011 Protocol v2.0 04/08/2011 Protocol Amendment Log v2.0 04/08/2011 PIS Phase II Amendment Log v1.0 to v2.0 04/08/2011 PIS Phase I Amendment Log v1.0 to v2.0 04/08/2011 PIS Phase II v2.0 (clean and tracked changes versions) 04/08/2011 PIS Phase I v2.0 (clean and tracked changes versions) 04/08/2011 Pregnancy PIS supporting information Pregnancy PIS and Consent v1.0 04/08/2011 Phase I/Phase II Consent Form Amendment Log v2.0 04/08/2011 Phase I/Phase II Consent Form v2.0 (clean and tracked changes versions) 04/08/2011 Participant Trial Card v1.0 04/08/2011 Trial Summary v2.0 (clean and tracked changes versions) 04/08/2011</p> <p>Additional Sites:</p> <p>Calderdale Royal-Uschi Hoffmann York Teaching Hospitals NHS Foundation Trust –David Bottomley Weston Park Hospital, Cancer Clinical Trials Centre –Linda Evans Bristol Haematology and Oncology Centre-Amit Bahl Huddersfield Royal Infirmary-Uschi Hoffmann Royal Free Hospital-Maria Vilarino-Varela Castle Hill Hospital-Mohammad Buitt Leicester Royal Infirmary-Steve Nicholson</p> <p>Changes of PI: Royal Bournemouth General Hospital-Susannah Brock (replaced Tom Geldart) Leeds St James's –Satinder Jagdev (replaced John Chester)</p> <p>Removal of PI: Newcastle General Hospital –Trevor Roberts Velindre Cancer Centre-Jim Barber Queen Elizabeth Hospital (Bham)-Emilio Porfiri</p>
20 March 2012	<p>Addition of new sites and PI as follows:</p> <p>Addenbrookes Hospital –Simon Pacey</p>
03 May 2013	<p>Change of documents: Covering letter 08/07/2013 Protocol v3.0 dated 23/05/2013(clean copy) Protocol v3.0 dated 23/05/2013 (tracked changes) Protocol Amendment Log v2.0 to v3.0 04/07/2013 Phase I Participant Information Sheet v3.0 04/07/2013(clean copy) Phase I Participant Information Sheet v3.0 04/07/2013(tracked changes) Phase I Participant Information Sheet Amendment Log v2.0 to v3.0 08/07/2013 Phase II Participant Information Sheet v3.0 04/07/2013 (clean copy) Phase II Participant Information Sheet v3.0 04/07/2013 (tracked changes) Phase II Participant Information Sheet Amendment Log v2.0 to v3.0 08/07/2013 Phase I/Phase II Participant Consent Form v3.0 04/07/2013 (clean copy) Phase I/Phase II Participant Consent Form v3.0 04/07/2013 (tracked changes) Phase I/Phase II Participant Consent Form Amendment Log v2.0 to v3.0 08/07/2013</p>

19 June 2014	<p>Change of documents:</p> <p>TOTEM Clinical Trial Protocol (from v4.0 to version 5.0).</p> <p>Update the Reference Safety Information (RSI) for temsirolimus to the EMC update on 06/12/2013.</p> <p>Change the status of cisplatin and gemcitabine from nIMPs to IMPs.</p> <p>To seek a labelling exemption: for cisplatin and gemcitabine as IMPs.</p> <p>To change the person or organisation authorised by the sponsor responsible for the CTA: from Dr Gareth Griffiths to Dr Richard Adams.</p> <p>Provide simplified IMPD: for temsirolimus 11/07/14</p> <p>Inform REC of non-substantial changes to protocol (v4.0 13.12.13)</p>
08 December 2015	<p>Change of documents:</p> <p>TOTEM Phase I PIS V7.0 12.11.15</p> <p>TOTEM Consent Form Phase I/Phase II V7.0 12.11.15</p> <p>TOTEM Clinical Trial Protocol (from v6.0 to v.7.0)</p> <p>To include Dr Simon Pacey as co-investigator</p> <p>To update Temsirolimus dose escalation schedule for Phase 1 with the inclusion of dose-level 3c</p> <p>To update Concomitant Medications Table</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported